AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15970116 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational intervention by nursing staff
Number of subjects: 70
Study 12582429 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate imipenem (prophylactic arm)
Number of subjects: 65
Study 12582429 — intervention group
Group type: COMPARATOR
Intervention: Delayed imipenem (therapeutic arm)
Number of subjects: 65
Study 10734844 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational package based on Present State Examination‐9 for initial assessment; duration: not specified
Number of subjects: 20
Study 10734844 — intervention group
Group type: EXPERIMENTAL
Intervention: File audit tool to evaluate effectiveness of education; duration: not specified
Number of subjects: 20
Study 8529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day)
Number of subjects: 19
Study 8529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/day)
Number of subjects: 19
Study 1686422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg QAM
Number of subjects: 0
Study 1686422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg QHS
Number of subjects: 0
Study 1686422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg BID
Number of subjects: 0
Study 1686422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6119512 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg 6‐hourly for adults and 40 mg/kg daily for children)
Number of subjects: 29
Study 6119512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6119512 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 29
Study 31226920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 0
Study 31226920 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 0
Study 30153581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 960
Study 30153581 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D replete
Number of subjects: 960
Study 28347733 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (SSI strain 1331)
Number of subjects: 4262
Study 28347733 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4262
Study 26597740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day elemental calcium)
Number of subjects: 836
Study 26597740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study 23374761 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy for 10 weeks delivered by trained occupational therapists.
Number of subjects: 192
Study 23374761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no occupational therapy during the study period).
Number of subjects: 192
Study 21458503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 10mg
Number of subjects: 18
Study 21458503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 21458503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 18
Study 19575328 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants instructed to generate and apply loci on a route to their work
Number of subjects: 0
Study 19575328 — intervention group
Group type: COMPARATOR
Intervention: Participants instructed to generate and apply loci on a route in their house
Number of subjects: 0
Study 17341558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (3 months of randomized and controlled physical activity-based lifestyle intervention)
Number of subjects: 21
Study 15562016 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 51
Study 15562016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12476058 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention (peer-developed diabetes management presentation)
Number of subjects: 72
Study 9803586 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C measles vaccine (4.0 log10pfu) administered at 6 months
Number of subjects: 0
Study 9803586 — intervention group
Group type: COMPARATOR
Intervention: Schwarz vaccine (3.7 log10pfu) given at 9 months
Number of subjects: 0
Study 7633972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg bd
Number of subjects: 687
Study 7633972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 2378442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmalagen (n = 10)
Number of subjects: 21
Study 2378442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alavac (n = 11)
Number of subjects: 21
Study 2378442 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated; n = 6)
Number of subjects: 21
Study 370940 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiation during induction in poor prognosis patients
Number of subjects: 0
Study 370940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus intrathecal methotrexate during early remission
Number of subjects: 0
Study 31470454 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin alone (C)
Number of subjects: 3
Study 31470454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin and vancomycin (CV)
Number of subjects: 3
Study 31010516 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy by vascular surgery
Number of subjects: 865
Study 31010516 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy by interventional cardiology
Number of subjects: 865
Study 31010516 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy by interventional radiology
Number of subjects: 865
Study 31010516 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy by other specialties
Number of subjects: 865
Study 28183564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol+paracetamol (Zaldiar; 325 mg paracetamol, 37.5 mg tramadol)
Number of subjects: 50
Study 28183564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25867186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganzfeld stimulation (visual deprivation)
Number of subjects: 35
Study 25867186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (visual deprivation)
Number of subjects: 35
Study 25867186 — intervention group
Group type: COMPARATOR
Intervention: Free viewing (control)
Number of subjects: 35
Study 23708155 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial injection of 1 × 10(5) autologous CD34(+) cells/kg
Number of subjects: 444
Study 23708155 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial placebo injection
Number of subjects: 444
Study 23708155 — intervention group
Group type: COMPARATOR
Intervention: Open‐label standard of care
Number of subjects: 444
Study 22251768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention with a goal of 10,000 steps/day
Number of subjects: 46
Study 22251768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 19642771 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA)
Number of subjects: 66
Study 19642771 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (RAE group)
Number of subjects: 66
Study 17381903 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-frequency questionnaire (FFQ)
Number of subjects: 238
Study 17381903 — intervention group
Group type: COMPARATOR
Intervention: 24-hour dietary recalls (24HDRs)
Number of subjects: 238
Study 17381903 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ
Number of subjects: 238
Study 15272091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 2481
Study 15272091 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 2481
Study 11401931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa inhibitor (12 patients, 86%)
Number of subjects: 14
Study 11401931 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients without CK‐MB elevation)
Number of subjects: 14
Study 9040650 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunoglobulins (IVIg)
Number of subjects: 0
Study 7510155 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal tubular parameters (alpha 1-microglobulin, N-acetyl-beta-D-glucosaminidase)
Number of subjects: 62
Study 7510155 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal tubular parameter (Tamm-Horsfall protein)
Number of subjects: 62
Study 7510155 — intervention group
Group type: COMPARATOR
Intervention: Albumin excretion (marker of glomerulum)
Number of subjects: 62
Study 3301478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 24
Study 3301478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31326395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 43
Study 31326395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 29972987 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group
Number of subjects: 48
Study 29972987 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction group
Number of subjects: 48
Study 26814319 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX U100 (self-adhesive resin cement)
Number of subjects: 10
Study 26814319 — intervention group
Group type: COMPARATOR
Intervention: RelyX ARC (conventional resin cement)
Number of subjects: 10
Study 25907772 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-PICC (4.5-French, 60-cm)
Number of subjects: 40
Study 25907772 — intervention group
Group type: COMPARATOR
Intervention: DL-CICC (16-gauge, 30-cm)
Number of subjects: 40
Study 25907772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DL-PICC and DL-CICC
Number of subjects: 40
Study 23699984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen
Number of subjects: 20
Study 23699984 — intervention group
Group type: COMPARATOR
Intervention: Physical barrier
Number of subjects: 20
Study 20876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (≤ 100 mmol/d)
Number of subjects: 0
Study 20876343 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet (≥ 200 mmol/d)
Number of subjects: 0
Study 20876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily with low-sodium diet
Number of subjects: 0
Study 20876343 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg once daily with high-sodium diet
Number of subjects: 0
Study 20876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 0
Study 15937679 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment (1 microg/kg IV bolus followed by 0.06 microg/kg/hr continuous perfusion)
Number of subjects: 52
Study 15937679 — intervention group
Group type: COMPARATOR
Intervention: Standard support treatment (0.9% ClNa delivered over 270 min)
Number of subjects: 52
Study 15937679 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment
Number of subjects: 52
Study 15937679 — intervention group
Group type: COMPARATOR
Intervention: Standard support treatment
Number of subjects: 52
Study 15937679 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment and Standard support treatment
Number of subjects: 52
Study 12797455 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous 677 TT genotype
Number of subjects: 405
Study 12797455 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin use (no folic acid vitamins)
Number of subjects: 405
Study 12797455 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin use (no folic acid vitamins) in high level SB defects
Number of subjects: 405
Study 11064609 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 12
Study 11064609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8636743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Number of subjects: 145
Study 8636743 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (50 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Number of subjects: 145
Study 8636743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2)
Number of subjects: 145
Study 8636743 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (50 mg/m2)
Number of subjects: 145
Study 1731134 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP mixed in the same syringe as PRP-T (group 1)
Number of subjects: 222
Study 1731134 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP and PRP-T given at separate injection sites (group 2)
Number of subjects: 222
Study 1731134 — intervention group
Group type: COMPARATOR
Intervention: DTP without PRP-T (group 3)
Number of subjects: 222
Study 6147691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 100
Study 6147691 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic chemotherapy
Number of subjects: 100
Study 6147691 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy
Number of subjects: 100
Study 31612533 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention
Number of subjects: 51
Study 31612533 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 51
Study 30218385 — intervention group
Group type: EXPERIMENTAL
Intervention: vHIT (video head impulse test)
Number of subjects: 36
Study 30218385 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men without hearing loss)
Number of subjects: 36
Study 30218385 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure hearing loss group
Number of subjects: 36
Study 27622544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 24
Study 27622544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25008473 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 servings of pistachios per day (2PD; 34% TF)
Number of subjects: 28
Study 25008473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of pistachios
Number of subjects: 28
Study 25008473 — intervention group
Group type: COMPARATOR
Intervention: Control diet (25% TF)
Number of subjects: 28
Study 25008473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 serving of pistachios per day (1PD; 30% TF)
Number of subjects: 28
Study 22326507 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell of baked cookies present
Number of subjects: 109
Study 22326507 — intervention group
Group type: COMPARATOR
Intervention: No-smell present
Number of subjects: 109
Study 22326507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cue exposure
Number of subjects: 109
Study 22326507 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cue exposure
Number of subjects: 109
Study 21291037 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) treatment
Number of subjects: 21
Study 21291037 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 21
Study 18565634 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlboro Lights (ML)
Number of subjects: 225
Study 18565634 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlboro Ultra Lights (MUL)
Number of subjects: 225
Study 18565634 — intervention group
Group type: COMPARATOR
Intervention: MFF (Control)
Number of subjects: 225
Study 15820805 — intervention group
Group type: COMPARATOR
Intervention: Serial transvaginal power Doppler ultrasound assessments throughout the follicular phase of ovarian stimulation.
Number of subjects: 34
Study 12588385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times a day for 2 weeks
Number of subjects: 24
Study 12588385 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet three times a day for 2 weeks
Number of subjects: 24
Study 12588385 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference expressed by patients
Number of subjects: 24
Study 11092773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation with midazolam
Number of subjects: 60
Study 11092773 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia only
Number of subjects: 60
Study 11092773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia and intravenous sedation
Number of subjects: 60
Study 8776215 — intervention group
Group type: EXPERIMENTAL
Intervention: E + P trial (exercise + postprandial)
Number of subjects: 12
Study 8776215 — intervention group
Group type: COMPARATOR
Intervention: P trial (postprandial)
Number of subjects: 12
Study 8776215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 12
Study 8776215 — intervention group
Group type: EXPERIMENTAL
Intervention: During exercise
Number of subjects: 12
Study 1629747 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin
Number of subjects: 61
Study 1629747 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus piperacillin
Number of subjects: 61
Study 6835891 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 100
Study 6835891 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 100
Study 30132008 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace neck-specific exercises
Number of subjects: 763
Study 29930161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (6 mg/m2 per day)
Number of subjects: 280
Study 29930161 — intervention group
Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction <30%
Number of subjects: 280
Study 29930161 — intervention group
Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction 30%-60%
Number of subjects: 280
Study 29930161 — intervention group
Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction >60%
Number of subjects: 280
Study 26702872 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (S)
Number of subjects: 51
Study 26702872 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 51
Study 26702872 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy (S + RT)
Number of subjects: 51
Study 26702872 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients >15 years
Number of subjects: 51
Study 26702872 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients <15 years
Number of subjects: 51
Study 25416925 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol plus carboxymethyl‐β‐glucan
Number of subjects: 82
Study 25416925 — intervention group
Group type: COMPARATOR
Intervention: Saline isotonic solution
Number of subjects: 82
Study 22178850 — intervention group
Group type: COMPARATOR
Intervention: No supplemental vitamin A or D (NAND)
Number of subjects: 168
Study 22178850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,750 IU vitamin A/kg dietary DM with no supplemental vitamin D (SAND)
Number of subjects: 168
Study 22178850 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplemental vitamin A and 1,860 IU vitamin D/kg dietary DM (NASD)
Number of subjects: 168
Study 22178850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,750 IU and 1,860 IU vitamin A and D/kg dietary DM (SASD)
Number of subjects: 168
Study 22178850 — intervention group
Group type: COMPARATOR
Intervention: No supplemental vitamin A (NAND and NASD combined)
Number of subjects: 168
Study 22178850 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet without supplemental vitamin A
Number of subjects: 168
Study 20951555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin for ≥ 6 months (Group I)
Number of subjects: 258
Study 20951555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin discontinued for ≥ 6 months (Group II)
Number of subjects: 258
Study 20951555 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve to vigabatrin (Group III)
Number of subjects: 258
Study 17386354 — intervention group
Group type: EXPERIMENTAL
Intervention: zofenopril (15 to 30 mg/d)
Number of subjects: 45
Study 17386354 — intervention group
Group type: COMPARATOR
Intervention: ramipril (2.5 to 5 mg/d)
Number of subjects: 45
Study 17386354 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg/d)
Number of subjects: 45
Study 10691158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 1 mg plus sulphonylurea
Number of subjects: 574
Study 10691158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg plus sulphonylurea
Number of subjects: 574
Study 10691158 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sulphonylurea
Number of subjects: 574
Study 9174875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing session (heat exposure: 76-87 degrees C, relative humidity 27-33%)
Number of subjects: 8
Study 9174875 — intervention group
Group type: COMPARATOR
Intervention: Control session (room temperature: 23 degrees C)
Number of subjects: 8
Study 8246029 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron plus dexamethasone
Number of subjects: 287
Study 8246029 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide plus dexamethasone and diphenhydramine
Number of subjects: 287
Study 3079939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg GTN spray
Number of subjects: 20
Study 3079939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg GTN spray
Number of subjects: 20
Study 3079939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg GTN spray
Number of subjects: 20
Study 3079939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual GTN
Number of subjects: 20
Study 3079939 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study 31714954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole preventive therapy (CPT) continued
Number of subjects: 172
Study 31714954 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole preventive therapy (CPT) discontinued (placebo)
Number of subjects: 172